TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04935359
Drug: Nab-paclitaxel
Normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Per locally approved formulation
Study: NCT04935359
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Per locally approved formulation
Study: NCT06276868
Drug: Dalcilib+letrozole+HP treatment group
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All participants received 150mg of darcilib once a day. Take it continuously for 21 days, then stop taking it for 7 days, with a treatment cycle of 28 days.~Letrozole 2.5mg once daily (premenopausal patients treated with OFS); Trastuzumab (8mg/kg first dose, 6mg/kg sequential) and Patuzumab (840mg first dose, 420mg/kg sequential) were administered intravenously every 3 weeks, or fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection (1200 mg pertuzumab plus 600 mg trastuzumab loading dose in 15 mL, followed by 600 mg pertuzumab plus 600 mg trastuzumab maintenance doses in 10 mL), both administered every 3 weeks.
Study: NCT06088290
Drug: Lurbinectedin
Normalized name: LURBINECTEDIN
DrugBank: Lurbinectedin (DB12674)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous Infusion
Study: NCT06208267
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: This is a 3 arm RCT using the three dosage regimens mentioned above. Placebo doses will be provided for the 0, 8, 16 and 24 hours without TXA
Study: NCT05424523
Drug: Omalizumab
Normalized name: Omalizumab
DrugBank: Omalizumab (DB00043)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients with confirmed diagnosis of allergic asthma, who were prescribed omalizumab
Study: NCT05665023
Drug: Bevacizumab + modified FOLFIRINOX
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab 5mg/kg D1, oxaliplatin 85 mg/m2 D1 + leucovorin 400mg/m2 D1 + irinotecan 150 mg/m2 D1 + 5-FU 2,400 mg/m2 46h continuous infusion, every other week
Study: NCT05392257
Drug: Rituximab + zanubrutinib + lenalidomide
Normalized name: Zanubrutinib
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab at 375mg / m2, Day 0; Zanubrutinib 160mg bid continuously oral; Lenalidomide 25mg qd oral on days 1-21; 28 days as a course of treatment
Study: NCT05870319
Drug: Pemetrexed
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 500 mg/m2 intravenous (IV) infusion (Q3W)
Study: NCT05870319
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: AUC 5 intravenous (IV) infusion (Q3W) 4cycles
Study: NCT05870319
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 75 mg/m2 intravenous (IV) infusion (Q3W) 4cycles
Study: NCT05246670
Drug: Palmidrol
Normalized name: Palmidrol
DrugBank: Palmidrol (DB14043)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PEA PO
Study: NCT06208748
Drug: Bezuclastinib in combination with sunitinib
DrugBank: Sunitinib (DB01268)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Bezuclastinib in combination with sunitinib (sutent)
Study: NCT06406140
Drug: Niacin tablets 500 mg
Normalized name: niacin Oral Tablet
DrugBank: Niacin (DB00627)
Approvals — FDA: no, EMA: no, PMDA: no
Description: tablets used to treat hyperphosphatemia and lower lipoprotein a concentration in End-Stage Renal Disease Patients Undergoing Hemodialysis
Study: NCT05249699
Drug: Isoniazid
Normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: prevent the development of tuberculosis
Study: NCT05751681
Drug: dydrogesterone (Duphaston, Abbott)
Normalized name: Dydrogesterone
DrugBank: Dydrogesterone (DB00378)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20 mg oral dose of dydrogesterone (Duphaston, Abbott)
Study: NCT05751681
Drug: Cetrotide
Normalized name: Cetrotide
DrugBank: Cetrorelix (DB00050)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.25 mg of Cetrotide (gonadotropin releasing hormone (GnRH) antagonist)
Study: NCT04977674
Drug: Naltrexone
Normalized name: Naltrexone
DrugBank: Naltrexone (DB00704)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pre-treatment with naltrexone 45 min before the ketamine infusion.
Study: NCT04977674
Drug: Ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants receive intravenous ketamine infusion (0.5 mg/kg over 40 min) at both study visits.
Study: NCT05648214
Drug: ALN-PNP - Part A
Normalized name: Echinacea, aerial parts
DrugBank: Echinacea (DB14240)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered by subcutaneous (SC) single ascending dose (SAD)
Study: NCT05576077
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pembrolizumab will be administered after TIL infusion and continue every 3-6 weeks for up to 2 years.
Study: NCT05511415
Drug: Oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxytocin solution, 20nM concentration
Study: NCT05511415
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexmedetomidine (10-9M to 10-4M)
Study: NCT04397679
Drug: Temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT04397679
Drug: Chloroquine
Normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT06153355
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered orally
Study: NCT06206421
Drug: Fezolinetant
Normalized name: Fezolinetant
DrugBank: Fezolinetant (DB15669)
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT05116189
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: IV infusion
Study: NCT05116189
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: IV infusion
Study: NCT05116189
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV infusion
Study: NCT06751485
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Active Comparator
Study: NCT06751485
Drug: Topotecan
Normalized name: Topotecan
DrugBank: Topotecan (DB01030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Active Comparator
Study: NCT05232825
Drug: Ocrelizumab IV
Normalized name: Ocrelizumab
DrugBank: Ocrelizumab (DB11988)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: IV Injection
Study: NCT05232825
Drug: Ocrelizumab SC
Normalized name: Ocrelizumab
DrugBank: Ocrelizumab (DB11988)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: SC Injection
Study: NCT05232825
Drug: Diphenhydramine IV
DrugBank: Diphenhydramine (DB01075)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive mandatory (corticosteroids and antihistamine) and optional (analgesic) prophylactic treatment before the start of each ocrelizumab infusion
Study: NCT05232825
Drug: Dexamethasone given orally
Normalized name: dexamethasone Oral Tablet
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants will receive mandatory (corticosteroids and antihistamine) and optional (analgesic) prophylactic treatment before the start of each ocrelizumab injection
Study: NCT05232825
Drug: Desloratadine given orally
Normalized name: Desloratadine
DrugBank: Loratadine (DB00455)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will receive mandatory (corticosteroids and antihistamine) and optional (analgesic) prophylactic treatment before the start of each ocrelizumab injection
Study: NCT05051735
Drug: Paracetamol
Normalized name: Paracetamol
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Paracetamol 500 mg
Study: NCT04773093
Drug: Continous Intravenous Lidocaine Infusion
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patient will recieve intravenous Lidocaine dose 1.5 mg/kg at the time of induction and after that will receive maintenance by continous intravenous Lidocaine infusion dose 2 mg/kg/hour until the completion of surgery
Study: NCT05175105
Drug: Mitapivat
Normalized name: Mitapivat
DrugBank: Mitapivat (DB16236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablets or granules
Study: NCT05175105
Drug: Mitapivat-matching placebo
Normalized name: Mitapivat
DrugBank: Mitapivat (DB16236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablets or granules
Study: NCT05653193
Drug: Interferon Gamma-1B 0.1 MG Per 0.5 ML Injection PLUS antifungals as standard of care
DrugBank: Interferon gamma-1b (DB00033)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients starting oral antifungal treatment for chronic pulmonary aspergillosis will be randomised 1:1 to additional interferon-gamma for 3 months or no additional treatment.
Study: NCT06112548
Drug: Bupivacain
Normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: low body weight (0.50%, 20cc) intraoperative periarticular injection
Study: NCT06112548
Drug: Paracetamol
Normalized name: Paracetamol
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV Paracetamol \[Ofirmev\] introduced every 6 hours after surgery
Study: NCT06112548
Drug: Tramadol
Normalized name: Tramadol
DrugBank: Tramadol (DB00193)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV Tramadol \[Ultram\] introduced when needed after surgery
Study: NCT05393674
Drug: Fedratinib Oral Capsule [Inrebic]
Normalized name: fedratinib Oral Capsule [Inrebic]
DrugBank: Fedratinib (DB12500)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 400 mg once daily p.o. from cycle 1-n, dose adjustment will be made according to the protocol
Study: NCT05393674
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 240 mg every 2 weeks i.v. from cycle 2-n
Study: NCT05098704
Drug: clopidogrel treatment
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 75 mg daily during 24 months
Study: NCT06680115
Drug: Sintilimab
Normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy stage: Sintilimab combined with GP regimen chemotherapy; Adjuvant chemotherapy stage: Sintilimab combined with Capecitabine
Study: NCT06681688
Drug: Omidria, {0.3%-1% Intraocular Solution}, VIGAMOX {0.5% moxifloxacin hydrochloride}, Kenalog {0.4 ml, 10mg/ml, triamcinolone acetonide}
DrugBank: Moxifloxacin (DB00218)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eyes in the Study Arm will be treated with the following intraoperative interventions: Intracameral (OMIDRIA) phenylephrine 1.0%/ketorolac 0.3%, intracameral moxifloxacin (0.5%), and subconjunctival triamcinolone acetonide (0.4 mL, 10mgs/mL).
Study: NCT00060515
Drug: RG2133 (2',3',5'-tri-O-acetyluridine)
Normalized name: Tri-O-acetyluridine
DrugBank: Uridine triacetate (DB09144)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04858256
Drug: Pacritinib
Normalized name: Pacritinib
DrugBank: Pacritinib (DB11697)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pacritinib will be dosed at 200mg twice daily.
Study: NCT05412875
Drug: Nicotine Replacement
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given JUUL
Study: NCT05264727
Drug: Dextrose
Normalized name: Dextrose
DrugBank: Dextrose, unspecified form (DB09341)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous graded glucose infusion using 50% dextrose will commence at 1mg/kg/min and increase to 2 (0900), 4 (1000) and 8mg/kg/min (1100) every 60 minutes
Study: NCT04850118
Drug: Control
Normalized name: Control
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Untreated Control Group 3
Study: NCT04836156
Drug: neoadjuvant chemotherapy upon in vitro PTC drug sensitivity screening for triple negative breast cancer
Normalized name: chicken breast preparation
DrugBank: Chicken (DB10519)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The choice of chemotherapy is based on the PTC drug sensitivity results.
Study: NCT04836156
Drug: neoadjuvant chemotherapy upon in vitro PTC drug sensitivity screening for luminal like breast cancer
Normalized name: chicken breast preparation
DrugBank: Chicken (DB10519)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The choice of chemotherapy is based on the PTC drug sensitivity results.
Study: NCT05804097
Drug: Hyperbaric oxygen
DrugBank: Oxygen (DB09140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 90-120 min sessions of hyperbaric oxygen treatment of 2.2-2.5 ATA
Study: NCT05521997
Drug: Telaglenastat
Normalized name: Telaglenastat
DrugBank: Telaglenastat (DB15232)
Approvals — FDA: no, EMA: no, PMDA: no
Description: -800 mg twice per day by mouth
Study: NCT05521997
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: * Standard of care~* Weekly administration of cisplain
Study: NCT06538207
Drug: ONO-4578
Normalized name: ONO-2952
DrugBank: ONO-2952 (DB14802)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specified dose on specified days
Study: NCT06538207
Drug: ONO-4538
Normalized name: ONO-2952
DrugBank: ONO-2952 (DB14802)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specified dose on specified days
Study: NCT06538207
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Specified dose on specified days
Study: NCT05246397
Drug: Sugammadex administration
DrugBank: Sugammadex (DB06206)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sugammadex will be given in 50 mg increments every five minutes for reversal of neuromuscular blockade until reaching a train-of-four ratio of 0.9
Study: NCT06538207
Drug: Levofolinate
Normalized name: sodium levofolinate
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Specified dose on specified days
Study: NCT06538207
Drug: Irinotecan
Normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Specified dose on specified days
Study: NCT06538207
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Specified dose on specified days
Study: NCT06538207
Drug: Nab-Paclitaxel
Normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Specified dose on specified days
Study: NCT05651178
Drug: Human CD19-CD22 Targeted T Cells Injection
Normalized name: CAR.CD19-Redirected T cells
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous genetically modified anti-CD19/CD22 CAR transduced T cells
Study: NCT04857307
Drug: Alprazolam
Normalized name: Alprazolam
DrugBank: Alprazolam (DB00404)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: * Pharmaceutical form: Inhalation powder.~* Study participants will receive Staccato alprazolam at prespecified time-points.
Study: NCT06125054
Drug: Ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: single dose of ketamine (0.71mg/kg bodyweight i.v. over 40 minutes)
Study: NCT00532519
Drug: citalopram (cipralex)
DrugBank: Citalopram (DB00215)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10-20 mg/day, for 12 weeks.
Study: NCT06443489
Drug: SHR-4849
Normalized name: SHR-A1904
DrugBank: SHR-A1904 (DB18702)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR-4849
Study: NCT05203289
Drug: BI 695501 - higher concentration
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 695501 - higher concentration
Study: NCT05203289
Drug: BI 695501 - lower concentration
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 695501 - lower concentration
Study: NCT05638776
Drug: REGEND001 cell therapy
Normalized name: hRPE cell therapy
DrugBank: ASP-7317 (DB18549)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transplantation of the cell product
Study: NCT05106387
Drug: Noninterventional
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No investigational treatment will be given in this noninterventional extension study
Study: NCT04798638
Drug: TY-9591 Tablets under Fasted Condition - Arm1
Normalized name: selenium sulfide
DrugBank: Selenium Sulfide (DB00971)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phase 1 (period 1) fasted from 10 hours prior to dosing with 80 mg TY-9591 tablet (p o, once) and 4 hours after dosing on day 1.
Study: NCT04798638
Drug: Osimertinib Mesylate Tablets under Fasted Condition - Arm1
Normalized name: Osimertinib Mesylate
DrugBank: Osimertinib (DB09330)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Phase 1 (period 2) fasted from 10 hours prior to dosing with 80 mg Osimertinib Mesylate Tablets (p o, once) and 4 hours after dosing on day 1.
Study: NCT04798638
Drug: Osimertinib Mesylate Tablets under Fasted Condition - Arm2
Normalized name: Osimertinib Mesylate
DrugBank: Osimertinib (DB09330)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Phase 1 (period 1) fasted from 10 hours prior to dosing with 80 mg Osimertinib Mesylate Tablets (p o, once) and 4 hours after dosing on day 1.
Study: NCT04798638
Drug: TY-9591 Tablets under Fasted Condition - Arm2
Normalized name: selenium sulfide
DrugBank: Selenium Sulfide (DB00971)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phase 1 (period 2) fasted from 10 hours prior to dosing with 80 mg TY-9591 tablet (p o, once) and 4 hours after dosing on day 1.
Study: NCT05493332
Drug: Oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 85mg/m2 IVdrip from hour 0 to 2 on D1，Q3W
Study: NCT05493332
Drug: Toripalimab
Normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 240mg IVdrip，D3, Q3W
Study: NCT05493332
Drug: Donafenib
Normalized name: DONAFENIB
DrugBank: CM-4307 (DB15414)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1g. P.O, BID, continuously
Study: NCT05559398
Drug: Glenzocimab
Normalized name: Glenzocimab
DrugBank: Glenzocimab (DB16175)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glenzocimab (ACT-017, Acticor Biotech) is formulated for IV administration as a sterile product with 20 mM sodium citrate and 130 mM sodium chloride buffer at pH of 5.0.~It is supplied for clinical trial use in vials containing 50 mL of the drug product at a concentration of 10 mg/mL.~Each vial contains 500 mg of glenzocimab. Two vials (2x500 mg) of glenzocimab should be administered concomitantly for eligible patients for a total daily dose of 1g.~Glenzocimab is intended to be administered as an IV infusion over 6 hrs, with 1/4 of the dose administered by a 15-minute bolus and 3/4 of the dose administered by 5h45min-slow infusion.
Study: NCT04709471
Drug: Nicotine
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will reduce their nicotine intake
Study: NCT04627922
Drug: N-Acetyl cysteine
Normalized name: N-Acetyl Cysteine
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The investigators will examine N-acetyl cysteine to treat concurrent tobacco use disorder and cannabis use in a double-blind, placebo-controlled RCT. Sixty regular cigarette smokers with current tobacco use disorder and cannabis use will be randomized to receive NAC 3600 mg per day over 8 weeks.
Study: NCT04327973
Drug: AT2221
Normalized name: AT2221
DrugBank: Miglustat (DB00419)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participants received ATB200 co-administered with AT2221 capsule (Miglustat)
Study: NCT05169268
Drug: ARIPiprazole Injection [Abilify]
Normalized name: aripiprazole Injection [Abilify]
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: subject already receiving the combination of Abilify Maintena and Rexulti
Study: NCT05169268
Drug: Brexpiprazole
Normalized name: Brexpiprazole
DrugBank: Brexpiprazole (DB09128)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: subject already receiving the combination of Abilify Maintena and Rexulti
Study: NCT05583383
Drug: camrelizumab
Normalized name: Camrelizumab
DrugBank: Camrelizumab (DB14776)
Approvals — FDA: no, EMA: no, PMDA: no
Description: camrelizumab was administered intravenously at a fixed dose of 200 mg, on the first day, once every 3 weeks, with a cycle of 3 weeks. Infusion for 30 min each time (no less than 20 min and no more than 60min); SOX: Oxaliplatin: 130 mg/m2, administered intravenously, on the first day, once every three weeks, and every three weeks is a cycle; S-1: according to BSA (\< \<1.25 40 mg；; 1.25-1.5 50 mg； \> \>1.5 60 mg), oral administration, d1-d14 twice a day, 3 weeks as a cycle; Trastuzumab was administered intravenously, with an initial loading dose of 8 mg/kg and a subsequent dose of 6 mg/kg, with a cycle of 3 weeks.
Study: NCT05291325
Drug: 3L PEG + Linaclotide
Normalized name: Linaclotide
DrugBank: Linaclotide (DB08890)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Before colonoscopy, particpant take linaclotide capsules for 3 days (1 tablet should be taken at least 30 minutes before the first meal every day). Particpant take 1500ml polyethylene glycol electrolyte solution within 1.5 hours from 20 p.m the night before the examination; and repeat the same dose of polyethylene glycol electrolyte solution 4-6 hours before colonoscopy.
Study: NCT05291325
Drug: 3L PEG
Normalized name: PEG
DrugBank: Polyethylene glycol (DB09287)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Particpant take 1500ml polyethylene glycol electrolyte solution within 1.5 hours from 20 p.m the night before the examination; and repeat the same dose of polyethylene glycol electrolyte solution 4-6 hours before colonoscopy.
Study: NCT05291325
Drug: 2L PEG + Linaclotide
Normalized name: Linaclotide
DrugBank: Linaclotide (DB08890)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Before colonoscopy, particpant take linaclotide capsules for 3 days (1 tablet should be taken at least 30 minutes before the first meal every day). Particpant take 1000ml polyethylene glycol electrolyte solution within 1 hours from 20 p.m the night before the examination; and repeat the same dose of polyethylene glycol electrolyte solution 4-6 hours before colonoscopy.
Study: NCT06557096
Drug: Osimertinib 80 MG
Normalized name: osimertinib 80 MG
DrugBank: Osimertinib (DB09330)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Osimertinib is taken orally at a dose of 80mg daily for a 28-day treatment period, followed by a sequential treatment of osimertinib 80mg daily taken orally for another 28 days.